Sonoma Pharmaceuticals
SNOA
17 hedge funds and large institutions have $1.32M invested in Sonoma Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
0% more capital invested
Capital invested by funds: $1.31M → $1.32M (+$1.21K)
0.01% less ownership
Funds ownership: 0.44% → 0.43% (-0.01%)
6% less funds holding
Funds holding: 18 → 17 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$64.2K |
| 2 |
Renaissance Technologies
New York
|
+$57.3K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.46K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.29K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$115K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$20.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $734K | +$57.3K | +354 | +8% |
|
|
BA
2
Bard Associates
Chicago,
Illinois
| $344K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $143K | +$64.2K | +397 | +70% |
|
|
4
Acadian Asset Management
Boston,
Massachusetts
| $45K | -$20.5K | -127 | -30% |
|
5
BlackRock
New York
| $26K | – | – | – |
|
|
RE
6
RBC Europe
London,
United Kingdom
| $8.26K | – | – | – |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $7K | +$1.29K | +8 | +22% |
|
8
US Bancorp
Minneapolis,
Minnesota
| $4K | – | – | – |
|
|
9
Osaic Holdings
Scottsdale,
Arizona
| $2K | +$1.13K | +7 | +88% |
|
10
Morgan Stanley
New York
| $1K | – | – | – |
|
|
11
Bank of America
Charlotte,
North Carolina
| $1K | +$1.46K | +9 | +450% |
|
|
HFS
12
HBC Financial Services
Seattle,
Washington
| $16 | – | – | – |
|
|
BCM
13
Bridgeway Capital Management
Houston,
Texas
| – | -$115K | -795 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$8K | -56 | Closed |
|
|
JFGIW
15
Johnson Financial Group Inc (Wisconsin)
Racine,
Wisconsin
| – | +$162 | +1 | New |
|
SNOA Hedge Fund Activity: Q1 2021 in Review
17 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2021, worth a combined $1.32M — up 0.09% from $1.31M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SNOA and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $64.2K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $115K sold.
- 17 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2021, down from 18 in Q4 2020.
- Funds reported $1.32M of Sonoma Pharmaceuticals stock for Q1 2021, up 0.09% quarter-over-quarter.
- 1 fund opened new Sonoma Pharmaceuticals positions in Q1 2021 and 2 closed out, a net change of -1 holder.
- The largest Sonoma Pharmaceuticals buyer in Q1 2021 was Vanguard Group, an estimated $64.2K added.
- The largest Sonoma Pharmaceuticals seller in Q1 2021 was Bridgeway Capital Management, an estimated $115K sold.
Based on aggregated 13F filings for Q1 2021.